Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT02495974 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.

NCT NCT02495974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02495974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Astellas Pharma Europe Ltd.
Phase
Observational
Overall status
Completed
Start date
September 8, 2015
Completion date
February 8, 2019
Enrollment
1,763 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer